734
Participants
Start Date
July 20, 2009
Primary Completion Date
September 28, 2012
Study Completion Date
January 26, 2018
Brivanib
Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Brivanib Placebo
Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
TACE Therapy
Trans-Arterial Chemo-Embolization Therapy
Local Institution, Taipei
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Taichung
Local Institution, Tainan City
Local Institution, Parkville
Local Institution, New Territories
Local Institution, Hong Kong
Local Institution, Bangkok
Local Institution, Bangkok
Local Institution, Marseille
Local Institution, Genova
University Of Virginia Health System, Charlottesville
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Tianjin
Local Institution, Toulouse
Local Institution, Bordeaux
Local Institution, Padua
Local Institution, Grenoble
Local Institution, Valencia
Local Institution, Valencia
Local Institution, Angers
Local Institution, Pisa
Local Institution, Lille
Local Institution, Lyon
Local Institution, Paris
Local Institution, Paris
The University Of Texas MD Anderson Cancer Center, Houston
Local Institution, Kaohsiung City
Richard Finn, M.D., Los Angeles
Local Institution, Clichy
Sharp Clinical Oncology Research, San Diego
Local Institution, Bondy
Local Institution, Créteil
Local Institution, Beijing
Local Institution, Changchun
Local Institution, Harbin
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution, Nanjing
Local Institution, Nanjing
Local Institution, Nanjing
Local Institution, Changzhou
Local Institution, Suzhou
Local Institution, Hangzhou
Local Institution, Changsha
Local Institution, Nanning
Local Institution, Busan
Local Institution, Chengdu
Local Institution, Guanzhou
Local Institution, Taegu
Local Institution, Xi'an
Local Institution, Kawasaki-shi
Local Institution, Chiba
Local Institution, Ogaki-shi
Local Institution, Tsu
Local Institution, Higashinari-ku
Local Institution, Osaka
Local Institution, Ōsaka-sayama
Local Institution, Kyoto
Local Institution, Nishinomiya-shi
Local Institution, Kure-shi
Local Institution, Kochi
Local Institution, Kumamoto
Local Institution, Kanazawa
Local Institution, Toyama
Montefiore Medical Center, The Bronx
Rhode Island Hospital, Providence
Seattle Cancer Care Alliance, Seattle
Local Institution, Capital Federal
Local Institution, Buenos Aires
Local Institution, Vancouver
Local Institution, Montreal
Local Institution, Roma
Local Institution, Toyoake
Local Institution, Kashiwa-shi
Local Institution, Hiroshima
Local Institution, Sapporo
Local Institution, Yokohama
Local Institution, Okayama
Local Institution, Osaka
Local Institution, Osaka
Local Institution, Sunto-gun
Local Institution, Chuo-ku
Local Institution, Minato-ku
Local Institution, Musashino-shi
Local Institution, Kyunggi-do
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Suwon
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY